Assembly Biosciences, INC Form 4 insider transactions

Jeanette M. Bjorkquist, an officer at Assembly Biosciences, Inc., sold 29 shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

Chief Medical Officer Anuj Gaggar acquired 14,000 restricted stock units following stockholder approval of an equity plan amendment.

Chief Manufacturing Officer Nicole S. White received 14,000 restricted stock units following shareholder approval of the 2018 Stock Incentive Plan amendment.

ASSEMBLY BIOSCIENCES, INC. Director Susan Mahony was granted 8,000 stock options with an exercise price of $24.11, aligning her interests with shareholders.

Assembly Biosciences director Lisa Johnson-Pratt was granted 8,000 stock options as part of a standard equity compensation plan.

Assembly Biosciences director Michael Houghton was granted 8,000 stock options as part of standard equity compensation.

Director Gina Consylman was granted 8,000 stock options in Assembly Biosciences, Inc. as part of a standard equity compensation arrangement.

Director Anthony E. Altig was granted 8,000 stock options in Assembly Biosciences, Inc. as part of a standard equity incentive.

Jeanette M. Bjorkquist, PFO and PAO of Assembly Biosciences, Inc., reported the acquisition of 3,500 restricted stock units following stockholder approval of a plan amendment.

Chief Scientific Officer William E. Delaney IV acquired 14,000 restricted stock units following stockholder approval of the company's equity incentive plan.

CEO and President Jason Okazaki acquired 50,750 restricted stock units following shareholder approval of an incentive plan amendment.

Gilead Sciences acquired 471,698 additional shares of Assembly Biosciences at $26.50 per share.

ASSEMBLY BIOSCIENCES officer Jeanette M. Bjorkquist reported an RSU grant and subsequent sell-to-cover transactions for tax obligations.

ASSEMBLY BIOSCIENCES' Chief Manufacturing Officer, Nicole S. White, received a restricted stock unit grant and sold shares to cover tax obligations.

Assembly Biosciences' Chief Medical Officer, Anuj Gaggar, was granted 26,000 restricted stock units, with a portion contingent on stockholder approval.

Assembly Biosciences' Chief Scientific Officer, William E. Delaney IV, was granted 26,000 restricted stock units, with a portion contingent on stockholder approval of a plan amendment.

Assembly Biosciences CEO Jason Okazaki was granted 94,250 restricted stock units, with a portion contingent on shareholder approval of a plan amendment.

Gilead Sciences, a 10% owner and director, acquired additional common stock and warrants in Assembly Biosciences through a private placement.

Assembly Biosciences officer Jeanette M. Bjorkquist was granted 300 restricted stock units and 600 stock options, aligning her compensation with the company's long-term performance.

Assembly Biosciences, Inc. Director Michael Houghton was granted 3,500 stock options with an exercise price of $15.81, aligning his interests with shareholder value.

ASSEMBLY BIOSCIENCES, INC. Director Susan Mahony was granted 3,500 stock options with an exercise price of $15.81, vesting by June 2026 or the 2026 annual meeting.

Assembly Biosciences, Inc. Director John G. McHutchison was granted 3,500 stock options with an exercise price of $15.81, aligning his interests with shareholder value.

Assembly Biosciences Director Lisa Johnson-Pratt was granted 3,500 stock options with an exercise price of $15.81, vesting by June 2026.

Assembly Biosciences, Inc. Director William R. Ringo was granted 3,500 stock options with an exercise price of $15.81, vesting upon the earlier of June 5, 2026, or the company's 2026 annual meeting.

Anthony E. Altig, a Director at Assembly Biosciences, Inc. (ASMB), was granted 3,500 stock options with an exercise price of $15.81, aligning his interests with the company's long-term performance.

Assembly Biosciences, Inc. director Gina Consylman was granted 3,500 stock options with an exercise price of $15.81, vesting by June 2026 or the 2026 annual meeting.

John G. McHutchison, a director at Assembly Biosciences, sold 757 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, reports acquisition of common stock and stock options.

Jeanette M. Bjorkquist, Principal Accounting Officer of Assembly Biosciences, reports acquisition and disposal of company stock and stock options.

CEO of Assembly Biosciences, Jason A. Okazaki, sold shares to cover tax obligations related to vested restricted stock units and received a grant of stock options.